Skip to content

Released Nov 9, 2023, before the open

10-Q filed Nov 9, 2023, 40 days after period end · 0001171843-23-006912

Q3 2023 · 10-Q
Revenue$0.00no prior Q3 2022 on fileno prior Q2 2023 on file
Net Income-$9.96MN/M vs Q3 2022N/M vs Q2 2023
EPS, diluted—
Operating Income-$11,926,000N/M
Operating Cash Flowderived-$5,922,000N/M
Free Cash Flowderived-$5,932,000N/M

What the release said

The release

Same quarter

MetricQ3 2023Q3 2022Q3 2021Q3 2020
Revenue$0.00———
Net Income-$9.96M-$11.98M-$5.98M-$9.15M
EPS Diluted——-$0.10-$0.18

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Compass Therapeutics, Inc. · CIK 1738021 · Engraved from SEC EDGAR